» Articles » PMID: 18676364

Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers

Overview
Date 2008 Aug 5
PMID 18676364
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

With the increasing demand of providing personalized medicine the need for biobanking of biological material from individual patients has increased. Such samples are essential for molecular research aimed at characterizing diseases at several levels ranging from epidemiology and diagnostic and prognostic classification to prediction of response to therapy. Clinically validated biomarkers may provide information to be used for diagnosis, screening, evaluation of risk/predisposition, assessment of prognosis, monitoring (recurrence of disease), and prediction of response to treatment and as a surrogate response marker. Many types of biological fluids or tissues can be collected and stored in biorepositories. Samples of blood can be further processed into plasma and serum, and tissue pieces can be either frozen or fixed in formalin and then embedded into paraffin. The present review focuses on biological fluids, especially serum and plasma, intended for study of protein biomarkers. In biomarker studies the process from the decision to take a sample from an individual to the moment the sample is safely placed in the biobank consists of several phases including collection of samples, transport of the samples, and handling and storage of samples. Critical points in each step important for high quality biomarker studies are described in this review. Failure to develop and adhere to robust standardized protocols may have significant consequences as the quality of the material stored in the biobank as well as conclusions and clinical recommendations based on analysis of such material may be severely affected.

Citing Articles

Evaluation of Serum Proteome Sample Preparation Methods to Support Clinical Proteomics Applications.

Twigg C, Perez J, Ryu J, Hanson B, Barrera Estrada V, Thomas S J Am Soc Mass Spectrom. 2024; 35(11):2659-2669.

PMID: 39263706 PMC: 11546599. DOI: 10.1021/jasms.4c00131.


Biospecimen Digital Twins: Moving from a "High Quality" to a "Fit-for-Purpose" Concept in the Era of Omics Sciences.

Nanni U, Ferroni P, Riondino S, Spila A, Valente M, Del Monte G Cancer Genomics Proteomics. 2023; 20(3):211-221.

PMID: 37093689 PMC: 10148068. DOI: 10.21873/cgp.20376.


Preservation of Proteins in Human Plasma through Metal-Organic Framework Encapsulation.

Wang Y, Morrissey J, Gupta P, Chauhan P, Pachynski R, Harris P ACS Appl Mater Interfaces. 2023; 15(15):18598-18607.

PMID: 37015072 PMC: 10484212. DOI: 10.1021/acsami.2c21192.


A virtual library for behavioral performance in standard conditions-rodent spontaneous activity in an open field during repeated testing and after treatment with drugs or brain lesions.

Szechtman H, Dvorkin-Gheva A, Gomez-Marin A Gigascience. 2022; 11.

PMID: 36261217 PMC: 9581716. DOI: 10.1093/gigascience/giac092.


The Future of Biomarkers in Veterinary Medicine: Emerging Approaches and Associated Challenges.

Perera T, Skerrett-Byrne D, Gibb Z, Nixon B, Swegen A Animals (Basel). 2022; 12(17).

PMID: 36077913 PMC: 9454634. DOI: 10.3390/ani12172194.


References
1.
Ferguson R, Hochstrasser D, Banks R . Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomics Clin Appl. 2010; 1(8):739-46. DOI: 10.1002/prca.200700380. View

2.
Lomholt A, Frederiksen C, Christensen I, Brunner N, Nielsen H . Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta. 2007; 380(1-2):128-32. DOI: 10.1016/j.cca.2007.01.022. View

3.
Holten-Andersen M, Schrohl A, Brunner N, Nielsen H, Hogdall C, Hogdall E . Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers. 2003; 18(3):170-6. DOI: 10.1177/172460080301800303. View

4.
Nielsen H, Brunner N, Frederiksen C, Lomholt A, King D, Jorgensen L . Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol. 2008; 43(2):242-8. DOI: 10.1080/00365520701523439. View

5.
Frederiksen C, Lykke J, Christensen I, Brunner N, Nielsen H . Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer. Scand J Clin Lab Invest. 2007; 67(5):545-52. DOI: 10.1080/00365510601166926. View